The Securities and Exchange Commission and Federal Trade Commission are investigating Abbott Laboratories’ baby-formula business, the company said. The SEC’s enforcement division sent a subpoena to Abbott
ABT,
+0.62%
in December requesting information about its powder infant-formula business and related public disclosures, the company said Friday in a securities filing.
